For research use only. Not for therapeutic Use.
Tinengotinib is the modulator of one or more protein kinases such as Aurora kinase and VEGFR kinase. Tinengotinib has the potential for the research of these kinase abnormalities diseases mediated, especially cancer-related diseases (extracted from patent WO2018108079A1)[1].
| Catalog Number | I045092 |
| CAS Number | 2230490-29-4 |
| Synonyms | 4-[9-(2-chlorophenyl)-6-methyl-2,4,5,8,12-pentazatricyclo[8.4.0.03,7]tetradeca-1(14),3,6,8,10,12-hexaen-13-yl]morpholine |
| Molecular Formula | C20H19ClN6O |
| Purity | ≥95% |
| InChI | InChI=1S/C20H19ClN6O/c1-12-18-20(26-25-12)23-16-10-17(27-6-8-28-9-7-27)22-11-14(16)19(24-18)13-4-2-3-5-15(13)21/h2-5,10-11H,6-9H2,1H3,(H2,23,25,26) |
| InChIKey | DQFCVOOFMXEPOC-UHFFFAOYSA-N |
| SMILES | CC1=C2C(=NN1)NC3=CC(=NC=C3C(=N2)C4=CC=CC=C4Cl)N5CCOCC5 |
| Reference | [1]. Wu, Yongqian, et al. Multi-kinase inhibitor compound, and crystal form and use thereof. Patent WO2018108079A1. |
